Advertisement
AXON or CNTN or INSM
Which Stock Would AI Choose? Axon Enterprise, Inc. (AXON) vs. Canton Strategic Holdings, Inc. (CNTN) vs. Insmed Incorporated (INSM) Stock Comparison
Key Takeaways
- AXON boasts the largest market cap at $32.4 billion and positive EBITDA of $196 million, driven by robust public safety technology demand.
- CNTN, a smaller $183 million market cap player, shows modest YTD gains of 6.6% amid blockchain ecosystem updates, but lacks revenue.
- INSM exhibits strong yearly performance with 94% gains, supported by biotech pipeline progress and analyst upgrades, despite recent dips.
- All three stocks have experienced recent pullbacks, with AXON down about 14% monthly due to valuation concerns, highlighting sector volatility.
- Tickeron AI favors INSM for superior trend consistency and catalysts in the current market.
Introduction
This comparison examines AXON, CNTN, and INSM—representing public safety technology, blockchain-digital assets, and biopharmaceuticals, respectively—in today's dynamic market. Traders seeking momentum plays and investors eyeing growth sectors will find value in analyzing their relative performance, recent catalysts, and risk profiles. With varying market caps and exposures, these stocks offer insights into technology-driven innovation versus biotech potential, aiding decisions on relative positioning and short-term trends.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops public safety solutions, including TASER devices, body cameras, and cloud-based evidence management software. Trading around $402 with a $32.4 billion market cap, the stock has seen YTD gains amid strong Q4 results, including 40% software revenue growth. Recent market activity reflects a pullback from 52-week highs near $886, influenced by valuation compression and tariff concerns, yet AI tool launches like a 911 co-pilot bolster sentiment. Earnings due May 6 highlight ongoing expansion in connected devices and services.
CNTN Overview and Recent Performance
Canton Strategic Holdings, Inc. (CNTN), formerly Tharimmune, focuses on institutional blockchain adoption via the Canton Network and digital asset treasury strategies, alongside residual biotech efforts. At about $3.23 per share and $183 million market cap, it trades in a 52-week range of $1.08-$9.08. Recent weeks feature quarterly ecosystem updates on Q1 growth, tokenomics shifts, and a $540 million private placement, driving modest YTD gains of 6.6% despite high volatility and zero revenue. Network validator activities shape cautious optimism.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) specializes in therapies for rare diseases, with ARIKAYCE for lung infections and pipeline candidates like brensocatib. Priced near $133 and holding a $28.8 billion market cap, shares range $64-$213 over 52 weeks. Recent performance includes YTD advances fueled by phase 3 trial progress and analyst upgrades, such as Guggenheim's $230 target. Pullbacks of 3-6% follow peaks, tempered by upcoming Q1 earnings on May 7 and investor conferences, reinforcing biotech momentum.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from over 351 available, each scanning thousands of tickers for optimal trades in stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML trend trading, swing trades, and TP/SL corridors across 5-minute to 60-minute timeframes. Standout stats include annualized returns up to 163%, win rates from 51% to 88%, profit factors of 1.5-7.1, and profit-to-drawdown ratios reaching 17. Tailored to current conditions like volatility in semis and data centers, they offer copy-trading for varied risk appetites. Explore these for data-driven insights into market opportunities.
Head-to-Head Comparison
AXON's established aerospace & defense model contrasts CNTN and INSM's biotech focus, with superior revenue ($2.78B) and EBITDA but recent monthly declines amid macro pressures. CNTN offers blockchain growth drivers like network adoption, yet trails in scale and stability, suiting high-risk traders. INSM leads yearly momentum (94%) via clinical catalysts, though negative EBITDA signals valuation sensitivity. Risks include AXON's debt, CNTN's execution hurdles, and INSM's trial outcomes; sentiment favors biotech rebound over tech pullbacks.
Tickeron AI Verdict
Tickeron's AI currently favors INSM with higher probability for near-term outperformance, citing 94% yearly gains, pipeline catalysts, and relative resilience despite dips. AXON and CNTN lag on recent trends, though earnings could shift dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileCNTN’s FA Score has 1 green FA rating(s), and INSM’s FA Score reflects 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- CNTN’s FA Score: 1 green, 4 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while CNTN’s TA Score has 4 bullish TA indicator(s), and INSM’s TA Score reflects 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- CNTN’s TA Score: 4 bullish, 3 bearish.
- INSM’s TA Score: 4 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +3.43% price change this week, while CNTN (@Biotechnology) price change was +1.24% , and INSM (@Biotechnology) price fluctuated -16.82% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.07%. For the same industry, the average monthly price growth was +1.71%, and the average quarterly price growth was +45.34%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.27%. For the same industry, the average monthly price growth was +4.35%, and the average quarterly price growth was +11.24%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
INSM is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Aerospace & Defense (+2.07% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-1.27% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | CNTN | INSM | |
| Capitalization | 31.7B | 185M | 25.1B |
| EBITDA | 320M | -10.29M | -1.08B |
| Gain YTD | -30.685 | 7.921 | -33.354 |
| P/E Ratio | 158.73 | N/A | N/A |
| Revenue | 2.98B | 0 | 820M |
| Total Cash | 737M | N/A | 1.22B |
| Total Debt | 1.83B | N/A | 580M |
AXON | INSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 72 | 58 | |
SMR RATING 1..100 | 80 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 65 | |
P/E GROWTH RATING 1..100 | 56 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (73) in the Biotechnology industry is in the same range as AXON (83). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
INSM's Profit vs Risk Rating (58) in the Biotechnology industry is in the same range as AXON (72). This means that INSM’s stock grew similarly to AXON’s over the last 12 months.
AXON's SMR Rating (80) in the Biotechnology industry is in the same range as INSM (100). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's Price Growth Rating (62) in the Biotechnology industry is in the same range as INSM (65). This means that AXON’s stock grew similarly to INSM’s over the last 12 months.
AXON's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that AXON’s stock grew somewhat faster than INSM’s over the last 12 months.
| AXON | CNTN | INSM | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | N/A | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 63% | 2 days ago 88% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 73% | 2 days ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 76% | 2 days ago 88% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 76% | 2 days ago 82% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 73% | 2 days ago 90% | 1 day ago 78% |
| Advances ODDS (%) | 6 days ago 74% | 2 days ago 87% | 1 day ago 71% |
| Declines ODDS (%) | 1 day ago 69% | 6 days ago 90% | 5 days ago 72% |
| BollingerBands ODDS (%) | 1 day ago 68% | 2 days ago 90% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 74% | 2 days ago 90% | 1 day ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ELIL | 21.81 | 1.06 | +5.10% |
| Direxion Daily LLY Bull 2X Shares | |||
| OCTP | 31.83 | N/A | +0.02% |
| PGIM S&P 500 Buffer 12 ETF - Oct | |||
| IVLU | 42.33 | -0.04 | -0.09% |
| iShares Edge MSCI Intl Value Factor ETF | |||
| SOVF | 28.25 | -0.12 | -0.43% |
| Sovereign's Capital Flourish Fund | |||
| TDVI | 30.94 | -0.67 | -2.12% |
| FT Vest Tech Div Trgt Inc ETF | |||
CNTN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNTN has been closely correlated with INSM. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if CNTN jumps, then INSM could also see price increases.
| Ticker / NAME | Correlation To CNTN | 1D Price Change % | ||
|---|---|---|---|---|
| CNTN | 100% | +2.51% | ||
| INSM - CNTN | 74% Closely correlated | +11.65% | ||
| RAIN - CNTN | 52% Loosely correlated | -0.68% | ||
| QURE - CNTN | 49% Loosely correlated | +5.32% | ||
| SNGX - CNTN | 46% Loosely correlated | +12.78% | ||
| APM - CNTN | 43% Loosely correlated | -0.88% | ||
More | ||||